Suven Life Sciences Limited converts 1.86 crore warrants

Suven Life Sciences Limited converted 1.8570133 crore fully paid preferential warrants into equity shares in the quarter ended September 30, 2026, after receiving Rs 248.8398 crore in consideration. Suven had Rs 320.0066 crore of unutilised proceeds from its Rs 857.6402 crore preferential issue at September 30, 2026.

What warrants did Suven convert in the September 2026 quarter?

Suven converted 1,85,70,133 fully paid warrants into an equal number of equity shares during the quarter ended September 30, 2026. The allotment was made on a preferential basis to 17 allottees after Suven received 100% of the warrant consideration, amounting to Rs 248.8398 crore.

The converted warrants had been allotted on July 8, 2026, according to the notes to Suven's unaudited results. This was a conversion within a previously approved preferential issue, rather than a new proposed issue: the board approved 6,40,02,999 convertible warrants for 23 allottees on May 13, 2025, and shareholders approved the issue on June 5, 2025.

The preferential conversion was separate from Suven's employee stock-option activity. In the preceding quarter ended June 30, 2026, Suven allotted 2,71,970 equity shares following exercises under its Employee Stock Option Scheme 2020, while the Nomination and Remuneration Committee had granted 1,33,200 options on May 13, 2026.

How much of Suven's preferential-issue proceeds remained unused?

Suven reported Rs 320.0066 crore of unutilised preferential-issue proceeds as of September 30, 2026. It disclosed total funds raised of Rs 857.6402 crore and utilisation of Rs 537.6336 crore, leaving the balance unspent at the reporting date.

The disclosed unutilised balance represented about 37% of the total preferential-issue proceeds, calculated from the three figures reported by Suven. The filing does not identify the individual purposes for which the Rs 537.6336 crore was used, nor does it provide an allocation or timetable for deployment of the Rs 320.0066 crore balance.

The September-quarter conversion brought in Rs 248.8398 crore after collection of the full warrant consideration. The filing separately presents the aggregate fund-utilisation position at September 30, 2026, so it does not state how much of that quarter's conversion consideration had been deployed by the same date.

How did the conversion affect Suven's equity share capital?

Suven's paid-up equity share capital was Rs 28.2563 crore at September 30, 2026, compared with Rs 26.3993 crore at June 30, 2026. The Rs 1.8563 crore increase over the quarter was close to the face-value amount represented by the 1,85,70,133 equity shares issued on conversion, with each share carrying a Re 1 face value.

Paid-up equity capital was also above Rs 22.7474 crore at September 30, 2025, an increase of Rs 5.5089 crore over 12 months. Suven does not disclose the number of convertible warrants remaining outstanding after the September-quarter conversion from the 6,40,02,999 warrants approved in 2025.

Suven recognised Rs 2.2096 crore of employee-benefit expense in the quarter ended September 30, 2026 for its 2020 employee stock-option scheme under Indian Accounting Standard 102, Share-based Payment. That expense and the 2,71,970 option-related shares allotted in the June 2026 quarter concern employee compensation, not the preferential warrants issued to 23 allottees.

What were Suven's standalone financial results for the quarter?

Suven reported a standalone net loss of Rs 16.3813 crore for the quarter ended September 30, 2026, compared with a loss of Rs 15.4451 crore in the quarter ended September 30, 2025. Revenue from operations increased to Rs 1.1986 crore from Rs 0.9192 crore, while total income, including other income, rose to Rs 7.933 crore from Rs 4.697 crore.

Standalone research and development expense was Rs 9.9193 crore in the September 2026 quarter, versus Rs 8.7732 crore a year earlier and Rs 12.756 crore in the June 2026 quarter. Total standalone expenses were Rs 24.3143 crore, compared with Rs 20.1421 crore in September 2025 and Rs 27.2085 crore in June 2026.

For the six months ended September 30, 2026, standalone net cash used in operating activities was Rs 40.3896 crore, compared with Rs 33.3975 crore in the corresponding 2025 period. Net cash used in investing activities declined to Rs 53.3517 crore from Rs 265.5189 crore, while financing activities generated Rs 92.576 crore against Rs 299.5428 crore a year earlier.

How did Suven's consolidated research spending and loss change?

Suven's consolidated net loss was Rs 106.9421 crore in the quarter ended September 30, 2026, lower than Rs 127.6103 crore in the June 2026 quarter but higher than Rs 77.3099 crore in the September 2025 quarter. For the six months ended September 30, 2026, the consolidated loss was Rs 234.5524 crore, compared with Rs 128.8268 crore in the corresponding 2025 half-year.

Consolidated research and development expense was Rs 100.2999 crore in the September 2026 quarter, down from Rs 123.831 crore in June 2026 but up from Rs 70.3213 crore a year earlier. Consolidated total expenses followed the same direction, declining sequentially to Rs 114.8751 crore from Rs 138.6997 crore, while exceeding Rs 82.0071 crore in September 2025.

Suven reported consolidated revenue from operations of Rs 1.1986 crore in the September 2026 quarter, compared with Rs 0.9192 crore a year earlier. The consolidated results include Suven Neurosciences, Inc. and Suven Neurosciences Pte. Ltd., the latter incorporated on July 14, 2026 and consolidated from that date; Suven reported research and development as its only business segment.

Conclusion

The September 2026 filing shows Suven converting 1.8570133 crore preferential warrants into equity after receiving Rs 248.8398 crore in full consideration, increasing the reported paid-up equity capital to Rs 28.2563 crore. The wider funding position shows Rs 537.6336 crore utilised from Rs 857.6402 crore raised, while Rs 320.0066 crore remained unutilised at September-end.

The next item to watch is Suven's disclosure on deployment of the Rs 320.0066 crore balance, because the September 30 filing gives no use-wise allocation or schedule. Subsequent filings may also show further conversions under the 6,40,02,999-warrant approval of June 2025 and changes in research and development expense, which was Rs 100.2999 crore on a consolidated basis in the September quarter.